Silo Pharma Inc. (NASDAQ: SILO) announced that its wholly owned managed AI agent subsidiary, QwikAgents, has expanded its platform with support for customer-supplied NVIDIA API keys and the addition of the Hermes agent runtime. The move allows customers to use their own NVIDIA API keys to access NVIDIA Nemotron models, making NVIDIA the fifth supported bring-your-own-key provider alongside Anthropic, OpenAI, Google, and DeepSeek. QwikAgents also added Hermes as an alternative to the OpenClaw runtime, enabling customers to select either option when creating an AI agent. Both runtimes operate on QwikAgents infrastructure, which includes managed hosting, persistent memory, model routing, and dedicated compute.
The expansion is significant for businesses seeking greater flexibility and cost control in AI agent deployment. By supporting customer-supplied API keys, QwikAgents reduces vendor lock-in and allows organizations to leverage existing NVIDIA agreements. The addition of Hermes provides a second runtime option, catering to diverse technical requirements and preferences. This positions QwikAgents as a more versatile platform in the competitive AI agent market.
Silo Pharma, a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, continues to innovate through its AI subsidiary. While its therapeutic focus remains on underserved conditions such as stress-induced psychiatric disorders, chronic pain, and central nervous system diseases, the QwikAgents development highlights its commitment to technological advancement. The company’s portfolio includes programs like SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis.
Investors and industry observers can find detailed information in the full press release available at https://ibn.fm/AXpqr. For ongoing updates on Silo Pharma, the company’s newsroom is accessible at https://ibn.fm/SILO. The announcement was distributed through AINewsWire, a specialized communications platform focused on artificial intelligence advancements. AINewsWire is part of the Dynamic Brand Portfolio within IBN, which offers extensive wire solutions via InvestorWire and editorial syndication to 5,000+ outlets.
The broader implications of this announcement extend to the AI and biotech sectors. For AI developers, QwikAgents’ support for multiple providers and runtimes could accelerate adoption by offering tailored solutions. For Silo Pharma, the success of QwikAgents may diversify revenue streams and enhance its technological profile. As AI continues to transform industries, such integrations are likely to drive innovation and competition. More information about AINewsWire’s services, including press release enhancement and social media distribution, is available on its website. The platform also provides corporate communications solutions for public and private companies.
